Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tianjin Zhongxin Pharmaceutical Group Acquires Zhongxin Medicine Chain

This article was originally published in PharmAsia News

Executive Summary

Zhongxin Pharmaceuticals recently announced the transfer of its subsidiary Zhongxin Medicine Chain Branch Company to its large shareholder Tianjin Zhongxin Pharmaceutical Group's drug distributor at 49.26 million yuan. As the biggest chain drugstore in Tianjin, Medicine Chain had attracted offers from China's major drug retailers such as Nepstar and Beijing Golden Elephant Chain Drugstore. Observers believe Zhongxin Pharmaceuticals' decision arose from its worries that Medicine Chain will not distribute its products once acquired by a competitor. Zhongxin Pharmaceuticals also said it may buy back Medicine Chain when the latter becomes profitable again. Tianjin is regarded a huge potential market for retail drugs, a fact borne out by the presence of pharmaceutical distributors such as Kaixinren, Laobaixing and Nepstar. (Click here for more - Chinese Language)

You may also be interested in...

Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD

Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.

Like Consumer Health Ad Claims About COVID-19, Customer Testimonials Are False And Misleading

Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts